As part of our XBORDR service line, our encognize Cross-Border Expansion Validation Partners collaborated throughout  with the Global Incubator Network (GIN) Austria and the Austrian Research Promotion Agency FFG during Q3 2025 to support strategic preparation for cohorts of innovative Life Science, BioTech and MedTech companies targeting market expansion into Japan and Singapore.

These healthcare / medical sector innovation-focused expansion support activities are fully embedded within our X.HEALTH initiative:
「Building the Future of Healthcare in Japan, Singapore/SEA and South Korea」,
an initiative that encompasses Expansion Strategic Preparation, Expansion De-Risking & Market Validation and Expansion Strategy Field Execution support delivered through group missions or bespoke team augmentation services with our medical experts network business partner.

As of October 2025, we have supported more than 30 startups & scaleups from 10 different countries with innovation spanning the entire Healthcare and Medical Ecosystem (MedTech, BioTech & Life Sciences, HealthTech & Digital Health) in their expansion journeys.

Examples of supported innovation to date include:

• AI SaMD for specific cancer types detection
• Algae-based biomaterial development
• AI Drug Discovery Platform
• AI-based sleep analysis
• Biofeedback device for amputees
• Mental health digital app
• Organoid-based regenerative medicine platform
• Digital early childhood developmental delay screening and intervention
• Bedsore detection device
• ...

Sample of outcomes realized for the companies we have supported (for different types of engagements and maturities) include:

• medical device early adopter identification and qualification
• joint validation project qualification with medical organization
• finding and confirming distributor for musculoskeletal disease prevention solution
• securing government-led ASEAN cross-country collaboration engagement
• regulatory / reimbursement strategy hypothesis and related execution pathways
• ...

We are excited to welcome the Taiwanese MedTech company MoleculeX to our X.HEALTH JAPAN 2025 Q1 edition!

What issues is MoleculeX addressing?
Oral Mucositis, a severe side effect of cancer treatments, causes painful ulcers that hinder therapy.
MoleculeX's MuCover® Patch and MuCoat® Glue provide the world's first large-area wound dressing for oral mucosa. Licensed in Taiwan in 2023, it is now in post-market clinical trials at major medical centers and preparing for FDA and CE Mark applications.

As part of our X.HEALTH JAPAN initiative, MoleculeX will benefit through Q1 from a 「Team Extension」 composed of both cross-border Expansion and Japan Medical Sector fractional experts who will support the design of a tailored, actionable Go-To-Market Strategy for their medical solution to enter the Japanese Market.

X.HEALTH JAPAN is an initiative co-delivered by XBORDR, an encognize G.K. Service Line, and xCare Inc., designed to specifically help HealthTech/MedTech companies de-risk and accelerate their Japan expansion through an expert-guided, pragmatic and customized approach.

Should you wish to know more about MoleculeX or the X.HEALTH JAPAN initiative, please do not hesitate to contact us!